Trial Profile
A Phase 2 Double-Blinded, Randomized, Placebo-Controlled, Multicenter Study Evaluating The Safety, Tolerability And Pharmacokinetics/ Pharmacodynamics Of PF-04360365 In Mild To Moderate Alzheimer's Disease Patients.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Ponezumab (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacokinetics
- 19 Jul 2012 Results presented at the 2012 International Conference on Alzheimer's Disease.
- 17 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 29 Nov 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.